Market Newsdesk

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) — Today, DraftKings Inc. (Nasdaq: DKNG) expands its executive team by hiring Brian Angiolet to oversee and optimize content creation and media strategy as the Company’s first ever Chief Media Officer. Most recently, Angiolet served as SVP and Chief Business Officer at Verizon Communications Inc. (“Verizon”) This hiring marks the first ever Chief Media Officer position at DraftKings.

“Brian brings invaluable experience to this new Chief Media Officer position and deeply understands how the virtuous circle among sports, gaming, and content has the potential to boost engagement,” said Jason Robins, DraftKings’ co-founder, CEO and Chairman of the Board. “As our media presence grows with the acquisition of VSiN, among other strategic moves, Brian’s creative ideas and insightful perspectives will further propel the possibilities of DraftKings content. Our warmest welcome to Brian, and we’re thrilled to have him aboard.”

During his tenure at Verizon, Angiolet spearheaded a number of high-profile, multi-billion-dollar content and advertising initiatives including broadcasting, sports and digital entertainment deals across Verizon’s Fios and media properties, partnerships with premier sports leagues like the NFL and NBA, and oversight of Verizon Wireless’ advertising and media portfolio. Most recently, he led the company’s 5G mobile edge computing partnership program and was instrumental in the launch of industry-defining deals with Amazon, Microsoft and IBM.

Angiolet’s duties as Chief Media Officer at DraftKings are effective Monday, April 26, 2021.

“The DraftKings arrow is pointing straight up and I see massive opportunity to unleash this platform and integrate it with the world of content,” said Angiolet. “To me it’s all about enhancing the experience we provide, and I look forward to working alongside the team and our partners at this important juncture for the company.”

With a growing presence of owned channels, including real-time fantasy plus sports betting news and analysis from DK Live alongside editorial insights at DK Nation, DraftKings is quickly establishing itself as both a product provider and resource for fans. The company has also been active to expand its reach with the recent acquisition of Vegas Sports Information Network, Inc. (“VSiN”), a trusted, multi-platform broadcast and content company in the sports betting space. Additionally, integration agreements with media titans Turner Sports and ESPN have further broadened visibility around DraftKings content, data and offers. Recently, the Company has also invested in Meadowlark and its roster of creators to deliver high-quality, original programming focused on sports.

For more information on DraftKings visit www.draftkings.com/about and download the DraftKings apps via iOS and Android.

About DraftKings

DraftKings Inc. is a digital sports entertainment and gaming company created to fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings is a multi-channel provider of sports betting and gaming technologies, powering sports and gaming entertainment for 50+ operators in 17 countries. DraftKings’ Sportsbook is live with mobile and/or retail betting operations in the United States pursuant to regulations in Colorado, Illinois, Indiana, Iowa, Michigan, Mississippi, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Tennessee, Virginia and West Virginia. DraftKings’ daily fantasy sports product is available in 8 countries internationally with 15 distinct sports categories. DraftKings is the official daily fantasy partner of the NFL, MLB, NASCAR, PGA TOUR and UFC as well as an authorized gaming operator of the NBA and MLB, an official betting operator of the PGA TOUR and the official betting operator of UFC. DraftKings also owns Vegas Sports Information Network, Inc. (VSiN), a multi-platform broadcast and content company.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside DraftKings’ control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see DraftKings’ Securities and Exchange Commission filings. DraftKings does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact

[email protected]

@DraftKingsNews

HERZLIYA, Israel, April 13, 2021 (GLOBE NEWSWIRE) — Safe-T® Group Ltd. (NASDAQ, TASE: SFET), a provider of secure access solutions and intelligent data collection, today announced the availability of a joint Zero Trust Access solution between its wholly owned subsidiary, Safe-T Data A.R Ltd. and Thales, designed to help organizations address their remote access scenarios with a simple and secure solution.

Organizations around the globe face a wide range of remote access requirements, such as:

• providing employees and third-party contractors simple access to internal resources
• providing access regardless of user physical location and device
• enforcing strong multi-factor authentication
• ensuring the security and privacy of the remote access session

In the world of digital transformation and work from home, the need for remote access to corporate resources has grown exponentially.

In order to provide their partners and customers with a best-of-breed secure remote access solution, Safe-T and Thales offer a Zero Trust Access solution, building on Safe-T ZoneZero® and Thales SafeNet Trusted Access. The combined solutions grant access to applications on a need-to-know basis ONLY, while giving all users (managed and un-managed) fast and seamless access to the resources they need.

“By offering this solution, we believe we will be able to deliver much value to our partners and customers.” Said Eitan Bremler, Co-Founder and VP Corporate Development, Safe-T. “The joint solution allows our customers to address their remote access scenarios with a simple and secure Zero Trust Access solution.”

“By integrating with Safe-T ZoneZero, SafeNet Trusted Access ensures that only validated users can access applications published by Safe-T,” said Francois Lasnier, vice president, Access Management solutions at Thales. “Our cloud-based access management service optimizes security and convenience for end users, while ensuring that organizations can migrate to the cloud securely by securing access to all applications no matter where they are located.”

Safe-T ZoneZero® introduces an evolution in the way organizations grant secure access to their services. Built on Safe-T’s Software Defined Perimeter technology and reverse-access patent, it offers true secure and transparent access for all users to internal applications and data.

SafeNet Trusted Access is a cloud-based access management service that combines the convenience of cloud and web single sign-on (SSO) with granular access security. By validating identities, enforcing access policies and applying Smart Single Sign-On, organizations can ensure secure, convenient access to numerous cloud applications from one easy-to-navigate console.

Together, Safe-T ZoneZero® and SafeNet Trusted Access establish a best-of-breed solution which controls who can access, and how access is granted, to internal and cloud services. Safe-T ZoneZero® controls the access to the corporate services, relying on SafeNet Trusted Access to enforce the appropriate access policy and authentication method.

About Safe-T®

Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of access solutions and intelligent data collection.
Our cloud and on-premises solutions mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of Safe-T’s zero trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud.

The wide range of access solutions, empowered by our patented reverse-access technology and proprietary routing technology, reduce organizations’ attack surface, improve their ability to defend against modern cyberthreats and enable them smooth digital transformation and to safely migrate to the cloud.

We also offer intelligent data collection cloud service, based on our world’s fastest and most advanced & secured business proxy network which enables clients to collect accurate, transparent & sensitive data from public online sources.

Safe-T’s solutions on AWS Marketplace are available here. For more information about Safe-T, visit www.safe-t.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Safe-T is using forward-looking statements in this press release when it discusses the advantages and capabilities of its ZoneZero™ solution, the advantages, capabilities and superiority of the joint solution with Thales and the potential of these solutions to address end-users and market requirements. Because such statements deal with future events and are based on Safe-T’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Safe-T could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Safe-T’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 22, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, Safe-T undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Safe-T is not responsible for the contents of third-party websites.

INVESTOR RELATIONS CONTACT

Chris Tyson     
Executive Vice President
MZ Group – MZ North America         
949-491-8235
[email protected]
www.mzgroup.us

Michal Efraty
+972-(0)52-3044404
[email protected]

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced an ongoing partnership with Alkemist Labs, an established leader in botanical plant testing, to collaborate with the National Institute of Standards and Technology (“NIST”) on efforts to help cannabis testing labs demonstrate and improve measurement capabilities and comparability. The tools developed by this NIST cannabis program will support measurements establishing legal, commerce, and safety claims through the development of fit-for-purpose analytical methodologies, production of Reference Materials, and implementation of NIST’s Cannabis Quality Assurance Program (“CannaQAP”).

As part of this collaboration, CV Sciences will prepare and provide hemp oil samples that NIST will distribute to laboratories that participate in CannaQAP. In addition, Alkemist Labs will provide initial measurements of cannabinoid levels in those samples.

Currently, marijuana and THC remain on the controlled substances list, although medical marijuana is legal in 33 states and recreational marijuana is legal in 11 states as well as the District of Columbia. The 2018 Farm Bill defined hemp as cannabis containing not more than 0.3% THC and removed hemp from the controlled substances list. These legal changes have required laboratories throughout the United States to implement quantitative analytical methods to distinguish cannabis raw material and finished products as marijuana or hemp.

“As one of the first accredited cannabis testing labs in California, Alkemist Labs has a long history as a strong advocate for rigorous laboratory standards for cannabis products,” said Alkemist Labs CEO Elan Sudberg. “We’re very pleased to be partnering with CV Sciences and NIST on this important effort to ensure that labs have the fit-for-purpose test methods they need to support high quality standards of cannabis products.”

CannaQAP will improve the accuracy and capability of cannabis product testing, which supports industry transparency and protects consumers. The CannaQAP will benefit forensic laboratories that are developing analytical methods to distinguish hemp from marijuana through quantitative measurements or screening thresholds; quality control laboratories testing cannabis products for strength and composition; regulatory laboratories testing for product compliance; and researchers conducting clinical trials on the safety and benefits of cannabis products.

“As the most trusted hemp-derived CBD company, CV Sciences was honored to be invited to partner with Alkemist Labs to assist NIST in its efforts to improve cannabis testing throughout the industry,” said Dr. Douglas Mackay, N.D., Senior Vice President of Scientific and Regulatory Affairs for CV Sciences. “We are dedicated to moving the CBD industry forward through science and advancing NIST’s CannaQAP program will play a pivotal role in helping the industry improve the scientific rigor and reproducibility between Cannabis testing labs.”

A full description of CannaQAP can be found here: https://www.nist.gov/programs-projects/nist-tools-cannabis-laboratory-quality-assurance.

About CV Sciences, Inc.

CV, or Curriculum Vitae, is Latin for “course of life”, and science is the pursuit of truth. CV Sciences: our name is our mission -improving quality of life through nature and science.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 7,300 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

About Alkemist Labs

Alkemist Labs is an ISO 17025 accredited contract testing laboratory specializing in plant authentication, botanical ingredient identification and quantitative analytical services to the Food & Beverage, Nutraceutical and Cosmeceutical industries. Located in a state-of-the-art facility in Garden Grove, California, Alkemist Labs offers clients a wide range of specialty research services to evaluate the identity, purity and quality of botanical raw materials, dietary ingredients and finished products. DEA registered 1, 2, 3n, and 4 for over 20 years, Alkemist is also approved to be on California Department of Food and Agriculture (CDFA) list for hemp testing. Alkemist Labs produces a complete line of Composite Reference Botanicals (CRBs), critical tools for botanical identity verification. Since it was founded in 1997, Alkemist Labs has become the ideal “Partner for Quality” to companies interested in producing high quality natural products requiring independent, third-party analysis, Stability/Shelf-life studies, Certification of Analysis and cGMP compliance. alkemist.com

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Investor Contact:
ICR
Reed Anderson
646-277-1260
[email protected]

Media Contact:
ICR
Cory Ziskind
646-277-1232
[email protected]

Alkemist Labs Media Contact:
Suzanne Shelton
847-922-5454
[email protected]

RANCHO SANTA FE, Calif., April 13, 2021 (GLOBE NEWSWIRE) — ValueSelling Associates, Inc. is honored to be selected to the 2021 Training Industry Top 20™ Sales Training and Enablement Companies List. This is the twelfth consecutive year that ValueSelling has received this distinction based on the following criteria:

• Breadth and quality of programs/services and audiences served.
• Ability to deliver training in learners’ preferred modalities.
• Industry visibility, innovation and impact.
• Strength of clients and geographic reach.
• Company size and growth potential.

Training Industry is the leading research and information resource for corporate learning leaders, and prepares the Training Industry Top 20 Sales Training and Enablement Companies List and Watch List. These lists report on critical sectors of the training marketplace to better inform learning and development professionals about the best and most innovative providers of training services and technologies. View Training Industry’s Top 20 list of Sales Training Companies, along with the Watch List.

“The quick adaptation and innovation of programs in response to customers’ needs during the pandemic has earned these organizations a spot on this year’s Top 20 Sales Training and Enablement Companies List,” said Ken Taylor, president of Training Industry, Inc. “Through virtual offerings and a focus on selling virtually, these companies prepare their clients’ sales force with the tools to succeed in today’s remote work environment.”

Julie Thomas, CEO of ValueSelling, adds, “It’s an honor to be evaluated and recognized once again by Training Industry as a leader in the sales training industry. We’re proud of our recently re-imagined Virtual Instructor-Led Training (VILT) offering that provides high quality and engaging virtual sales training and coaching to help companies flourish and drive sales results, while organizations continue to feel the ripple effect from the pandemic.”

ValueSelling Associates offers the only proven sales methodology, the ValueSelling Framework®, that makes complex B2B selling simple by focusing on the buyer and the value they receive by doing business with a company. Because the sales methodology is a simple and repeatable process, people use it. It helps organizations grow revenue, improve margins, and reduce costs.

ValueSelling Associates offers customized sales training, sales coaching, and consulting services to keep it simple and drive sales results. Consistently ranked as a Top 20 Sales Training company by both Training Industry and Selling Power, ValueSelling Associates is now proud to add Gartner Magic Quadrant Leader to that list.

To gain ValueSelling insight:

• Sign up for a ValueSelling webinar

• Listen to The B2B Revenue Executive Experience podcast

• Explore the ValueSelling blog

• Visit the newsroom for media coverage on ValueSelling

• Learn more about our Virtual Instructor-Led Training (VILT) sessions

About ValueSelling Associates, Inc.

ValueSelling Associates, a leading global sales training company, offers a practical methodology for selling on value, not price. The ValueSelling Framework® is a proven formula that simplifies the complex B2B sale, and the Vortex Prospecting™ program provides a repeatable process that increases connections and conversions to the revenue pipeline. Once trained on the ValueSelling method, organizations grow revenue and increase productivity. Since 1991, thousands of professionals around the world have chosen ValueSelling Associates for customized training, reinforcement and consulting to drive sales results. For more information, visit www.valueselling.com and follow us on Twitter at @ValuSelling.

Media contact:

Maria Doyle
Doyle Strategic Communications
+1-781-964-3536
[email protected]

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/9c258fc5-2081-4993-a541-0b4374a2cebb

TORONTO, April 13, 2021 (GLOBE NEWSWIRE) — Worksport Ltd (OTC: WKSP) (or the “Company”) a developer and manufacturer of high quality, modular, and attractively priced tonneau covers and solar-powered systems for light-duty trucks, today announced that Steven Rossi, Chief Executive Officer, will present an overview of Worksport at the Benzinga Cleantech Small Cap Conference on April 22, 2021 at 10:10 am. Following the presentation and Q&A session, Rossi will be speaking at a panel discussion titled Emerging Innovations and the Companies Behind Them at 1:00pm. This panel will highlight companies pushing for a paradigm shift in the way our economy functions to create sustainable value.

Investors interested in attending the virtual conference and listening to the presentation and panel discussion via webcast, should register visiting https://www.benzinga.com/events/small-cap/clean-tech/ . For more information regarding the conference or to schedule a one-on-one meeting with management, please email [email protected] or your Benzinga representative directly.

To stay up-to-date on all the latest Worksport news… investors, supporters, and shareholders are encouraged to follow the company’s social media accounts on Twitter, Facebook, LinkedIn, and Instagram, as well as sign up for the company’s newsletters at www.worksport.com and www.goterravis.com.

About Worksport Ltd.

Worksport Ltd. (currently OTCQB: WKSP) develops and manufactures high quality, modular, and attractively priced tonneau covers and solar-powered systems for light-duty trucks such as the Sierra, Silverado, Canyon, RAM, Ford F-Series, et al. and consumer-oriented adventures & purposes, where portable energy is a necessity. Available soon to pre-order, the modular, redefining Worksport TerraVis^™ tonneau cover system is being mindfully designed for the jobsite contractor and off-road, light-duty trucker, for work and play, to sustainably supply extra energy for those additional miles. Expected to launch by end of year 2021, its allied TerraVis COR^™ mobile energy storage system (ESS), will be another redefining product targeted for vacationers, second-home owners, and campers. Plans are also being constructed to expand with grid micro-charging stations to provide convenience and efficiency in recharging to smaller form-factor EVs. For more information, please visit www.worksport.com and www.goterravis.com.

Connect with Worksport:

LinkedIn

Facebook

Twitter

Instagram

For further information please contact:

Mr. Steven Rossi
CEO & Director
Worksport, Ltd
T: 1-888-554-8789
E: [email protected]

Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK

Reported Positive Pre-Clinical Data Associated with Artelo’s Proprietary CBD Cocrystal

$11.2 Million of Cash and Cash Equivalents and Marketable Securities as of February 28, 2021

LA JOLLA, Calif., April 13, 2021 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the second quarter of its fiscal year ended February 28, 2021 and provided a business update.

“We are pleased to report continued clinical and corporate progress during the second quarter of 2021,” stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Most recently, we dosed the first patient in our Phase 1/2 Cancer Appetite Recovery Study (CAReS) of ART27.13, marking a major milestone for Artelo. We believe ART27.13 has the potential to become a standard of care treatment for cancer anorexia, a wasting syndrome associated with significant weight loss that affects more than 60% of all cancer patients and is a leading cause of mortality in this population. Our goal is to complete the study within approximately twelve months, and we anticipate announcing meaningful clinical updates as we advance through the trial.”

During the quarter, the Company announced positive pre-clinical data associated with its proprietary CBD cocrystal, ART12.11, showing potential pharmacodynamic interactions of its components, cannabidiol (CBD) and tetramethylpyrazine (TMP), in cell-based models of cancer.  The study observed enhanced effects between CBD and TMP versus either compound alone, reinforcing Artelo’s CBD cocrystal’s potential for improved efficacy and differentiation from other forms of CBD. The full data is expected to be disclosed at a future scientific conference.

“We ended the quarter with approximately $11.2 million of cash and cash equivalents, and marketable securities, which provides us more than sufficient runway to execute on a number of key upcoming milestones that we believe have the potential to drive significant value for shareholders,” added Randy Schreckhise, Vice President Finance and Operations. “At the same time, we continue to expand our senior management and board of directors with key additions, as well as enhance our intellectual property protection with additional patent filings,” continued Mr. Schreckhise. “We believe we have built a robust therapeutic pipeline addressing underserved, multi-billion dollar markets and we remain highly encouraged by the outlook for the business.”

Second Quarter Fiscal 2021 Highlights:

• Announced positive laboratory data associated with proprietary CBD cocrystal demonstrating co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile.
• Announced non-clinical research collaboration with Trinity College Dublin, Ireland to further investigate ART27.13 for the treatment of cancer cachexia.
• Filed a composition of matter patent application regarding a new solid dosage formulation, including its method of use, with the UK Patent Office for ART27.13.
• Appointed Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer.
• Appointed Tamara A. Seymour, CPA, and Gregory R. Reyes, M.D., Ph.D. to Artelo’s Board of Directors.

Second Quarter Fiscal 2021 Financial Results:

• Operating expenses for the three months ended February 28, 2021 were $1,867,509 compared to $1,370,534 for the same period in 2020. The company’s operating expenses were primarily related to professional fees for ongoing regulatory requirements, research and development and general and administrative expenses.
• Net loss was approximately $1,865,921, or $0.11 per basic and diluted share for the quarter ended February 28, 2021 compared to a net loss of $1,370,126, or $0.40 per basic and diluted share for the quarter ended February 29, 2020.
• As of February 28, 2021, the Company has approximately $11,218,461 in cash and cash equivalents and marketable securities.

About Artelo Biosciences

Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected]

Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver

Senti Bio is potentially eligible to receive
upfront, opt-in and milestone payments exceeding $645 million

PHILADELPHIA, April 13, 2021 (GLOBE NEWSWIRE) — Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced a collaboration and option agreement with Senti Biosciences, a leading gene circuit company, to apply Senti Bio’s gene circuit technology to the development of next-generation precision gene therapies directed toward specific cell types in the central nervous system (CNS), eye or liver. Created from novel and proprietary combinations of DNA sequences, gene circuits reprogram cells with biological logic to sense inputs, compute decisions and respond to their environments for defined therapeutic applications.

“As the leader in gene therapy, we are constantly evaluating emerging technologies to complement our in-house expertise and welcome collaborations with innovators like Senti Bio, which we hope will further accelerate our efforts to unlock the full potential of gene therapy for patients living with genetic disease,” said Joseph La Barge, chief business officer, Spark Therapeutics.

Senti Bio’s gene circuit technologies include high-throughput approaches to design and test highly potent and specific Smart Sensors that are responsive to cell-type- and/or cell-state-specific biomarkers. These Smart Sensors include synthetic promoters, which are compact DNA sequences engineered to moreprecisely regulate the expression of therapeutic genes. Spark Therapeutics will apply Senti Bio’s Smart Sensors gene circuit platform towards the goal of developing gene therapies that achieve cell type- or disease-selective expression of therapeutic payloads.

“Breaking barriers for patients living with genetic disease requires evaluating opportunities to further our proven gene therapy platform, and we are thrilled to collaborate with Senti Bio, which is at the forefront of using synthetic biology to engineer gene circuits to create therapies with enhanced therapeutic properties that increase efficacy, precision and control,” said Federico Mingozzi, Ph.D., chief scientific officer, Spark Therapeutics. “We look forward to leveraging Senti Bio’s high-throughput synthetic promoter capabilities to develop novel gene therapies directed toward specific cell types in the central nervous system, eye or liver.”

Under the terms of the agreement, Senti Bio will be responsible for designing, building and testing cell type- and disease specific-synthetic promoters for use in developing certain CNS, eye or liver-directed gene therapies. Spark Therapeutics will receive the option to exclusively license a defined number of synthetic promoters emerging from the collaboration for use in developing gene therapy products in specified indications. Upon option exercise, Spark Therapeutics will be responsible for conducting preclinical, clinical and commercialization activities for any gene therapy candidates that incorporate Senti Bio’s licensed synthetic promoters.

Senti Bio will receive an upfront payment as well as funding to support its research activities, and upon option exercise will be eligible to receive an option exercise payment as well as development, regulatory and sales milestone payments in addition to royalties on a per product basis. The aggregate potential value of upfront, opt-in and milestone payments to Senti Bio may exceed $645 million.

Gene Therapy Partner of Choice

Breaking barriers to unlock the full potential of gene therapy for patients living with genetic disease requires complementing our in-house expertise with collaborators across industry and academia. Spark Therapeutics has been at the forefront of gene therapy research for more than eight years, advancing more than a dozen clinical trials against cell targets in the retina, liver and central nervous system. We strive to bring together the best and brightest technologies, scientific minds and innovators to bring more gene therapies to more patients living with genetic disease.

About Spark Therapeutics

At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We currently have four programs in clinical trials. At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.

Media Contact:

Kevin Giordano
[email protected]
(215) 294-9942

ORANGE COUNTY, CA, April 13, 2021 (GLOBE NEWSWIRE) — Tobi West (CISSP, GCFE, CCFE), Professor and Department Chair of the Computer Information Systems (CIS) and Computer Services Technology (CST), was recently nominated as being a Woman of Distinction in the field of Education by State Senator Thomas J. Umberg (D-Santa Ana).

The Women of Distinction program was established as part of the Senate’s celebration of Women’s History Month in March.   Senator Umberg has continued this tradition locally to pay tribute to these remarkable female leaders who have made extraordinary accomplishments in their professions and whose service has made a significant contribution to the community in the 34th Senate District.  Senator Umberg noted, “As the husband and father of two such strong women, and grandfather of two (soon to be three) granddaughters, I know full well the importance of both fostering education, independence, and confidence in women and respectfully honoring their many achievements.”   .

In addition to her position as Professor and Department Chair at Coastline College, Tobi West has developed and hosts GenCyber girls’ camps and workshops for teen girls in cybersecurity and technology education and career pathways called CyberTech Girls.   Professor West has spent her professional educational career innovating offerings to provide the best for students.    She is the ultimate mentor for others who are looking to pursue a career in cybersecurity.   Under her leadership, Tobi West has blazed a pathway for the next generation of female leaders.

“It is an incredible honor to be nominated and considered for Senator Umberg’s Women of Distinction award this year. I continuously strive to provide students with the pathways to help them with academic achievement and career preparation to enter the cybersecurity workforce.  I believe hands-on activities and connections with professional mentors are the way to build a diverse workforce and protect our Nation’s security.” Tobi West

Coastline’s Computer Information Systems (CIS) and Computer Services Technology (CST) is recognized as a Center of Academic Excellence in Cyber Defense Education (CAE-CDE) by the National Security Agency (NSA) and the Department of Homeland Security (DHS).   There are only six community colleges in California that hold this distinct designation and Coastline was the first community college in California to receive this prestigious designation in 2014.

About Coastline College:

Coastline College is accredited by the Western Association of Schools and Colleges.  For eight consecutive years, Coastline College was selected as one of the top 150 colleges by The Aspen Institute for Community College Excellence which is considered the most prestigious designation for community colleges. Coastline delivers flexible courses and services that cultivate and guide diverse student populations across the globe to complete pathways leading to the attainment of associate degrees, certificates, career readiness, and transfer to four-year colleges/universities.  

Dawn Willson
Coastline College - Marketing and Communications Director
7142416186
[email protected]

LOS ANGELES, April 13, 2021 (GLOBE NEWSWIRE) — Preferred Bank (NASDAQ: PFBC), one of the larger independent commercial banks in California, today announced plans to release its financial results for the first quarter ended March 31, 2021 after the close of market on Tuesday, April 20, 2021.  On the following day, Wednesday, April 21, 2021, management will host a conference call at 2:00 p.m. Eastern (11:00 a.m. Pacific). The call will be simultaneously broadcast over the Internet.

Interested participants and investors may access the conference call by dialing 844-826-3037 (domestic) or
412-317-5182 (international) and referencing “Preferred Bank.” There will also be a live webcast of the call available at the Investor Relations section of Preferred Bank’s website at www.preferredbank.com.

Preferred Bank’s Chairman and CEO Li Yu, President and Chief Operating Officer Wellington Chen, Chief Financial Officer Edward J. Czajka, Chief Credit Officer Nick Pi and Deputy Chief Operating Officer Johnny Hsu will discuss Preferred Bank’s financial results, business highlights and outlook. After the live webcast, a replay will be available at the Investor Relations section of Preferred Bank’s website. A replay of the call will also be available at 877-344-7529 (domestic) or 412-317-0088 (international) through May 5, 2021; the passcode is 10155105.

About Preferred Bank

Preferred Bank (the “Bank”) is one of the larger independent commercial banks headquartered in California. The Bank is chartered by the State of California, and its deposits are insured by the Federal Deposit Insurance Corporation, or FDIC, to the maximum extent permitted by law. The Bank conducts its banking business from its main office in Los Angeles, California, and through eleven full-service branch banking offices in California (Alhambra, Century City, City of Industry, Torrance, Arcadia, Irvine, Diamond Bar, Pico Rivera, Tarzana and San Francisco (2)) and one branch in Flushing, New York. Preferred Bank offers a broad range of deposit and loan products and services to both commercial and consumer customers.  The Bank provides personalized deposit services as well as real estate finance, commercial loans and trade finance to small and mid-sized businesses, entrepreneurs, real estate developers, professionals and high net worth individuals. Although originally founded as a Chinese-American Bank, Preferred Bank now derives most of its customers from the diversified mainstream market but does continue to benefit from the significant migration to California of ethnic Chinese from China and other areas of East Asia.